Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs

Instituto de Investigacion Sanitaria La Fe

Status and phase

Terminated

Phase 2

Conditions

Venous Thromboembolism

Treatments

Drug: Apixaban 2.5 MG

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT04106700

APIXABAN

Details and patient eligibility

About

Interventional, no-randomized, open-label, and single arm multicentre study of apixaban for the prevention of thromboembolic events during induction therapy in transplant-eligible patients with newly diagnosed multiple myeloma who receive bortezomib, thalidomide, and dexamethasone (VTD) during the induction phase of therapy prior to autologous stem cell transplantation (ASCT). The current study is designed to evaluate the efficacy and safety of apixaban during the induction period. Efficacy will be defined as a composite endpoint of acute symptomatic proximal and distal deep venous thrombosis, pulmonary embolism, VTE related deaths, and acute ischemic stroke.

Full description

This study is designed to test the efficacy and safety of the oral anti factor Xa apixaban 2.5 mg given twice daily as a prophylaxis of VTE in transplant-eligible patients with multiple myeloma during the induction therapy with VTD.

Induction therapy prior to ASCT will consist in no less than 4 and no more than 6 cycles of VTD, depending on treatment response. Duration of each cycle is 4 weeks if there is not any disease or treatment-related complication; therefore, treatment duration will be around 4-6 months. Daily Prophylaxis with apixaban will continue up to a maximum of 14 days after the last dose of thalidomide. In addition, there will be an additional observation period of 14 (± 7) days, starting the day after the last dose of study medication (until 28 days after the end of the last cycle of VTD).

Enrollment

60 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Signed written informed consent
Subjects must have documented newly diagnosed symptomatic multiple myeloma requiring front-line treatment.
Patients should be considered transplant-eligible
Subjects will receive front-line induction therapy with a triplet regimen consisting of bortezomib, thalidomide and dexamethasone (VTD).
To enter to the study at the same time of start anti myeloma induction therapy.
Ages eligible for study: 18 to 70 years.
Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status score ≤2.

Exclusion criteria

Patients with the diagnosis of plasma cell leukemia, Waldenström macroglobulinemia, POEMS syndrome or amyloidosis of light chain.
Patients with smouldering multiple myeloma or monoclonal gammopathy of undeterminated significance.
Patients considered non-transplant-eligible.
Grade ≥2 of peripheral neuropathy.
Prior history of documented any venous thromboembolism and arterial thrombosis event
Active or high risk of bleeding.
Need for on-going anticoagulant or antiplatelet treatment.
Contraindication of anticoagulant prophylaxis
Uncontrolled hypertension: systolic blood pressure >200 mmHg and/or diastolic blood pressure >100 mmHg.
HIV, HBV or HCV-positive active.
Expected survival <6 months.
Weight <40 Kg.
Low platelet count (<50 x109/L).
ALT >3x UNL, bilirubin >2x ULN.
Creatinine clearance <30 mL/min.
Women of childbearing potential who are unwilling to use an acceptable method of contraception.
Women of childbearing potential who are pregnant or breastfeeding.
Women with a positive pregnancy test on enrollment, prior to investigational product administration.
Administration of any investigational drug currently or within 30 days prior to planned enrollment into this study.
Subjects unwilling or unable to comply with study medication instructions or study procedures (e.g. bilateral lower extremity venous ultrasonography).
Known allergies to ingredients contained in apixaban.
Use of any contraindicated medications with apixaban (see section 5.4.1).